Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series

In this case series, 10 patients with recalcitrant lichen planopilaris (LPP) were treated with oral tofacitinib, a Janus kinase (JAK) inhibitor, at doses of 5 mg twice or three times daily for 2–19 months. The treatment was administered either as monotherapy or in combination with other therapies. Eight patients showed clinical improvement, with significant reductions in the LPP Activity Index (LPPAI) from an average of 6.22 before treatment to 3.08 after treatment (p = .0014), indicating a reduction in LPPAI ranging from 30 to 94%. One patient experienced a 10-pound weight gain, but no other adverse effects were reported. The study concluded that oral tofacitinib could lead to measurable improvement in recalcitrant LPP.